Clinical Features of the Initial Cases of 2009 Pandemic Influenza A (H1N1) Virus Infection in China, New England Journal of Medicine, vol.361, issue.26, pp.2507-2517, 2009. ,
DOI : 10.1056/NEJMoa0906612
Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase, Journal of Clinical Virology, vol.47, issue.1, pp.34-37, 2010. ,
DOI : 10.1016/j.jcv.2009.09.030
Pandemic influenza A(H1N1)v viruses currently circulating in New Zealand are sensitive to oseltamivir, Eurosurveillance, vol.14, issue.30, p.19282, 2009. ,
Universal primer set for the full-length amplification of all influenza A viruses, Archives of Virology, vol.146, issue.12, pp.2275-2289, 2001. ,
DOI : 10.1007/s007050170002
U s eo ft h e oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment, Journal of the American Medical Association, vol.282, issue.13, pp.1240-1246, 1999. ,
Duration of influenza A virus shedding in hospitalized patients and implications for infection control, Infection Control and Hospital Epidemiology, vol.28, issue.9, pp.1071-1076, 2007. ,
Prolonged shedding of influenza A(H1N1)v virus: two case reports from France, Eurosurveillance, vol.14, issue.49, 2009. ,
E ffects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection, Clinical Infectious Diseases, vol.50, issue.7, pp.963-969, 2010. ,
Quantification of the Influenza Virus Load by Real???Time Polymerase Chain Reaction in Nasopharyngeal Swabs of Patients Treated with Oseltamivir, The Journal of Infectious Diseases, vol.188, issue.4, pp.578-580, 2003. ,
DOI : 10.1086/377046